- Quickfact: Genomics Services
- Quickfact: HuBase™
- Quickfact: MuBase®
- Quickfact: OncoExpress™
- Quickfact: XenoBase®
- White Paper: Optimize Target Identification and MOA Studies
- Webinar: Next Generation Syngeneic Models to Facilitate Immuno-Oncology Research
- Webinar: How to Detect, Characterize, and Evaluate CAR-T Cell Therapies
- Quickfact: MuScreen™
- Quickfact: MuPrime™ Tumor Homografts
- Quickfact: Genetically Modified Models
- White Paper: Key Applications of Syngeneic Models to Maximize I/O Translatability
- White Paper: Exploring Translational Capabilities of PDX Models across In Vivo, In Vitro, and Ex Vivo Applications
- White Paper: Immuno-Oncology: 3 Strategies for Applying Humanized Models
- Publication: Key In Vivo Model Uses Across Cancer Drug Target Research
- Webinar: Legeraging 3D In Vitro Models for Oncology Drug Discovery
- Webinar: In Silico Applications for In Vitro Drug Discovery
- Quickfact: CrownSyn™
- Quickfact: Organoid Co Culture
- Quickfact: OmniScreen: Large Scale Cancer Cell Line Screening
- White Paper: When and How to Use Tumor Organoids in Drug Discovery
- Fact Sheet: 3D Cell Culture Platform In Vitro/Ex Vivo Assays for Cancer Pharmacology
- White Paper: Integrated Oncology Protfolio for Target Identification and Mechanism of Action Elucidation
- Market Report: Comparison of 2D cell lines, 3D spheroids and 3D patient-derived systems
- Webinar: 3 Strategies to Identify Clinically Predictive Biomarkers in the Preclinical Space
- Publication: Decreasing Glioma Secondary Mutations to Delay Tumour Recurrence
- Publication: Barcode Deep NGS-Based Profiling of Oncology Samples
- Publication: The design, analysis and application of mouse clinical trials in oncology drug development
- Quickfact: Mouse I/O RNA-Seq Panel
- Quickfact: Genomics Services
- Quickfact: DMPK Services
- Quickfact: CrownSyn